Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

neurodegenerative

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?

Healthcare leaders in the European Union should begin preparing for a breakthrough now

- PMLiVE

Theranexus takes Alzheimer’s drug combo into clinic

150-subject phase 1b trial to start at eight centres in France

- PMLiVE

Tox trouble stalls Sosei/Allergan Alzheimer’s drug

Surprise findings from primate studies

Biogen Idec building

Big debate follows Biogen/Eisai’s Alzheimer’s study unveiling

Mixed results prompted a 10% share drop for both companies

- PMLiVE

Daily Brief: Janssen’s HIV vaccine, Q2 results, Biogen’s Alzheimer’s data

News from pharma, biotech and healthcare

Biogen Idec building

Biogen and Eisai claim mid-stage win for Alzheimer’s drug

Says drug slowed down progression of cognitive decline

- PMLiVE

Anavex sets up trial of ‘triple-action’ Alzheimer’s drug

US biotech's novel drug is latest to join war on Alzheimer's

- PMLiVE

Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat

Another BACE candidate is abandoned, leaving just one remaining in the pipeline

Celgene building

Celgene bulks up pipeline again with $2.1bn Prothena deal

Acquires candidates with potential in Alzheimer’s, ALS and dementia

- PMLiVE

Boehringer abandons PDE-targeted Alzheimer’s drug

But will keep testing the candidate in schizophrenia

- PMLiVE

Smart watch epilepsy monitor cleared by FDA

Approval could potentially clear the way for insurers to reimburse its cost

- PMLiVE

Pfizer and IBM’s tech-enabled ‘Parkinson’s house’

Pharma firm looks to technology to help it unlock the doors to breakthrough treatments

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links